{"paper_id":"2b3b505a-0e9f-4cb0-94b4-9c689f08b8fe","body_text":"All content published in this journal is licensed under the Creative Commons Attribution 4.0 \nInternational License (CC BY 4.0).\n1\nInternational Journal\nISSN 2675-5157                                                                               vol. 2, n.17, 2026\nOpen Minds\nAcceptance date: 29/09/2026\nVioleta Bösel da Costa\nCatholic University of Pelotas\nSabrina Fischer Monteiro \nAtitus Educação\nEduarda Rodrigues Pagliarini \nCatholic University of Pelotas\nGabriela Bianchini Ribeiro \nFederal University of Santa Maria \nLuiza Coll Duquia\nCatholic University of Pelotas\nLettyere Coelho Rolim \nOlinda School of Medicine\nGabriel Dai Prá da Silva\nUniversity of Passo Fundo \nMariana Artigas Araújo \nCatholic University of Pelotas\nCaroline Marson Dal Mas \nUniversity of Passo Fundo\nMillene Regina Roxy Almeida Santos \nXavier \nUniversidad del Norte (UniNorte)\nGLP-1 AND GIP AGONISTS: A \nNEW THERAPEUTIC APPROACH \nFOR ENDOMETRIOSIS\nARTICLE 5\n\nDOI https:/ /doi.org/10.22533/at.ed.51572172608095\nArticle 5 GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS\n2\nAbstract: Endometriosis is a chronic, in -\nflammatory, estrogen-dependent gyneco -\nlogical disease that affects approximately \n10% of women of reproductive age and is \na major cause of chronic pelvic pain, infer-\ntility, and reduced quality of life. Althou -\ngh conventional treatments are based pri -\nmarily on hormonal therapies and surgical \napproaches, many cases present with symp-\ntom recurrence or therapeutic limitations. \nRecently, glucagon-like peptide-1 (GLP-\n1) and glucose-dependent insulinotropic \npolypeptide (GIP) receptor agonists—wi -\ndely used in the treatment of obesity and \ntype 2 diabetes mellitus—have attracted \ninterest due to their anti-inflammatory, \nimmunomodulatory, and metabolic effects. \nThe present study aims to discuss the poten-\ntial mechanisms by which GLP-1 and GIP \nagonists may represent a new therapeutic \nstrategy for endometriosis. This is a narra-\ntive review of the literature based on recent \npublications regarding the pathophysiology \nof endometriosis, systemic inflammation, \ninsulin resistance, obesity, and the actions \nof incretin mimetics. The findings suggest \nthat these medications may help reduce \nthe inflammatory process, modulate the \nimmune response, control metabolism, \nand slow the progression of endometriotic \nlesions. Although clinical evidence is still \nlimited, preliminary results point to a pro-\nmising area of research that could expand \nthe therapeutic options available to patients \nwith endometriosis.\nKeywords: Endometriosis; GLP-1; GIP; \nTirzepatide; Semaglutide; Inflammation; \nWomen’s Health.\nINTRODUCTION\nEndometriosis is a chronic inflamma-\ntory condition characterized by the pre -\nsence of endometrium-like tissue outside \nthe uterine cavity, primarily affecting the \novaries, pelvic peritoneum, and uterosacral \nligaments. It is estimated that the disease \naffects approximately 190 million women \nworldwide, representing a significant pu -\nblic health problem.\nDespite its high prevalence, the pa -\nthophysiology of endometriosis remains \ncomplex and multifactorial, involving \nhormonal, genetic, immunological, and \ninflammatory changes. The peritoneal en-\nvironment of patients exhibits increased \nproduction of pro-inflammatory cytokines, \nangiogenic factors, and pain mediators, \nwhich promote the survival and prolifera-\ntion of endometriotic implants.\nIn recent decades, numerous studies \nhave demonstrated the close relationship \nbetween systemic inflammation, energy \nmetabolism, and gynecological diseases. At \nthe same time, the development of GLP-\n1 receptor agonists and dual GLP-1/GIP \nagonists has revolutionized the treatment \nof obesity and type 2 diabetes mellitus, \nshowing benefits that extend beyond glyce-\nmic control.\nIn addition to significant weight loss, \nmedications such as semaglutide, liragluti-\nde, and tirzepatide exhibit anti-inflamma-\ntory, antioxidant, and immunomodulatory \nproperties, sparking interest in their applica-\ntion for chronic inflammatory conditions. \nIn this context, the hypothesis arises that \nsuch agents may also exert beneficial effects \non the pathophysiology of endometriosis.\n\nDOI https:/ /doi.org/10.22533/at.ed.51572172608095\nArticle 5 GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS\n3\nOBJECTIVE\nT o analyze the available scientific evi-\ndence on the potential benefits of GLP-1 \nreceptor agonists and dual GLP-1/GIP \nagonists in the treatment of endometriosis, \ndiscussing their pathophysiological mecha-\nnisms and future therapeutic prospects.\nMETHODOLOGY\nThis is a narrative literature review. \nWe searched for publications indexed in \nthe PubMed, Scopus, Web of Science, and \nVirtual Health Library (BVS) databases, \nusing the following search terms in English \nand Portuguese: “Endometriosis,” “GLP-\n1 receptor agonists,” “GIP ,” “Tirzepatide,” \n“Semaglutide,” “Inflammation,” “Obesity,” \n“Metabolic Dysfunction,” and “Women’s \nHealth.”\nOriginal articles, systematic reviews, \nmeta-analyses, and experimental studies pu-\nblished between 2015 and 2025 were inclu-\nded. The selection prioritized studies related \nto the inflammatory pathophysiology of \nendometriosis, the mechanisms of action of \nGLP-1 and GIP agonists, and the potential \napplications of these drugs in inflammatory \nand gynecological diseases.\nFollowing a critical analysis of the lite-\nrature, the data were organized into thema-\ntic categories to discuss the main mechanis-\nms involved.\nDISCUSSION\nEndometriosis as a Systemic \nInflammatory Disease\nThe contemporary view of endome -\ntriosis goes beyond the concept of an exclu-\nsively gynecological disease. It is now recog-\nnized that the condition involves a persistent \nsystemic inflammatory state, characterized \nby elevated levels of pro-inflammatory cy -\ntokines such as TNF- α, IL-1 β, IL-6, and \nIL-8.\nThese mediators promote angiogene-\nsis, cell proliferation, and neuronal sensiti-\nzation, contributing to chronic pain and the \nprogression of lesions. Furthermore, immu-\nnological alterations facilitate evasion of \ncellular surveillance mechanisms, allowing \nectopic implants to persist.\nThis inflammatory scenario represents \na potential therapeutic target for new phar-\nmacological approaches.\nThe Relationship Between \nMetabolism, Obesity, and \nEndometriosis\nAlthough endometriosis has traditio -\nnally been associated with women with a \nlower body mass index, recent studies de -\nmonstrate a complex interaction between \nenergy metabolism, insulin resistance, and \ninflammation.\nObesity promotes increased produc -\ntion of inflammatory adipokines, including \nleptin and resistin, as well as reduced adi -\nponectin levels, thereby fostering a syste -\nmic pro-inflammatory state. These factors \nmay exacerbate pain, fatigue, and disease \nprogression.\n\nDOI https:/ /doi.org/10.22533/at.ed.51572172608095\nArticle 5 GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS\n4\nAdditionally, metabolic changes can \ndirectly influence the activity of macropha-\nges and immune cells present in the perito-\nneal microenvironment, contributing to the \nmaintenance of chronic inflammation.\nMechanisms of Action of GLP-1 \nAgonists\nGLP-1 is an incretin hormone pro -\nduced by intestinal L cells in response to \nfood intake. Its agonists promote increased \ninsulin secretion, reduced glucagon levels, \ndelayed gastric emptying, and increased \nsatiety.\nHowever, recent studies show that the \nbenefits of these medications extend beyond \nmetabolic control. Several studies have \nidentified anti-inflammatory properties as-\nsociated with reduced expression of TNF-α, \nIL-6, and C-reactive protein.\nFurthermore, GLP-1 agonists appe -\nar to modulate macrophage activity, redu -\ncing polarization toward pro-inflammatory \nphenotypes and promoting a less aggressive \nimmune environment.\nThese mechanisms may be particularly \nrelevant in endometriosis, whose progres -\nsion depends on the maintenance of a per-\nsistent inflammatory state.\nThe Potential of Dual GLP-1/GIP \nAgonists\nTirzepatide, the first dual GLP-1/GIP \nagonist approved for the treatment of obesi-\nty and type 2 diabetes, demonstrates supe-\nrior results in reducing body weight and im-\nproving metabolic markers when compared \nto standalone GLP-1 agonists.\nGIP also performs important immu -\nnometabolic functions, influencing the re-\ngulation of inflammation and energy me -\ntabolism. Experimental studies suggest that \nthe combined activation of GLP-1 and GIP \nreceptors may potentiate systemic anti-in -\nflammatory effects.\nAlthough there are still no robust cli-\nnical trials directly evaluating tirzepatide in \npatients with endometriosis, the observed \nbiological mechanisms suggest a potential \nbenefit in reducing the disease’s inflamma-\ntory activity.\nImpact on Pain and Quality of Life\nChronic pelvic pain is the main symp-\ntom of endometriosis and is closely linked \nto neuroinflammation. Recent evidence \nshows that GLP-1 agonists may exert neu-\nroprotective and pain-modulating effects by \nreducing inflammatory mediators and oxi-\ndative stress.\nIn addition, the significant weight \nloss observed with these medications may \nimprove physical and psychological aspects \nthat are often compromised in women with \nendometriosis, including fatigue, self-este -\nem, sleep quality, and mental health.\nTherefore, the potential benefits of \nthese drugs may extend beyond the reduc-\ntion of lesions to encompass an overall im-\nprovement in quality of life.\nCurrent Limitations of the Evidence\nDespite growing scientific interest, the \nuse of GLP-1 and GIP agonists in endome-\ntriosis is still in the early stages of research. \nMuch of the available evidence derives from \nexperimental studies, animal models, and \npathophysiological extrapolations.\n\nDOI https:/ /doi.org/10.22533/at.ed.51572172608095\nArticle 5 GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS\n5\nThere is a lack of randomized clinical \ntrials that directly evaluate outcomes such as \npain reduction, lesion regression, impact on \nfertility, and improvement in quality of life \nin patients with endometriosis.\nThus, although the results are promi-\nsing, it is not yet possible to routinely re -\ncommend these therapies for the treatment \nof the disease outside of research protocols \nor approved indications for obesity and \ndiabetes.\nCONCLUSION\nEndometriosis is a complex inflamma-\ntory disease that continues to pose a signifi-\ncant therapeutic challenge. GLP-1 receptor \nagonists and dual GLP-1/GIP agonists are \nemerging as potential therapeutic alternati-\nves due to their anti-inflammatory, immu-\nnomodulatory, metabolic, and neuroprotec-\ntive effects.\nThe pathophysiological mechanisms \ninvolved suggest that these medications \nmay act on multiple aspects of the disease, \nincluding reducing systemic inflammation, \nmodulating the immune system, improving \nenergy metabolism, and potentially allevia-\nting chronic pain.\nAlthough the current evidence is still \npreliminary, the growing number of studies \npoints to a new and promising line of resear-\nch in the treatment of endometriosis. Future \nclinical trials will be essential to determine \nthe efficacy, safety, and applicability of these \nagents in gynecological practice.\nREFERENCES\nAgarwal SK, Chapron C, Giudice LC, et al. \nClinical diagnosis of endometriosis: a call to \naction. American Journal of Obstetrics and \nGynecology. 2019;220(4):354.e1-354.e12.\nBulun SE. Endometriosis. New England Jour-\nnal of Medicine. 2009;360(3):268-279.\nChapron C, Marcellin L, Borghese B, Santulli \nP . Rethinking mechanisms, diagnosis and ma-\nnagement of endometriosis. Nature Reviews \nEndocrinology. 2019;15(11):666-682.\nGiudice LC. Endometriosis. New England \nJournal of Medicine. 2010;362(25):2389-2398.\nKakoly NS, Moran LJ, Teede HJ, Joham AE. \nCardiometabolic risks in women with en -\ndometriosis. Human Reproduction Update. \n2018;24(5):553-568.\nMuller TD, Finan B, Bloom SR, et al. Gluca -\ngon-like peptide 1 (GLP-1). Molecular Meta-\nbolism. 2019;30:72-130.\nNanda S, Jain A, Marwah N. Anti-inflamma-\ntory effects of GLP-1 receptor agonists: current \nevidence and future directions. Diabetes Re -\nsearch and Clinical Practice. 2023;198:110609.\nSurrey E, Taylor HS, Giudice LC, et al. Lon -\ng-term outcomes of endometriosis manage -\nment. Fertility and Sterility. 2024;121(1):23-\n35.\nWilding JPH, Batterham RL, Calanna S, et \nal. Once-weekly semaglutide in adults with \noverweight or obesity. New England Journal \nof Medicine. 2021;384(11):989-1002.\nJastreboff AM, Aronne LJ, Ahmad NN, et al. \nTirzepatide once weekly for the treatment of \nobesity. New England Journal of Medicine. \n2022;387(3):205-216.\nFerrero S, Barra F , Leone Roberti Maggiore U. \nCurrent and emerging therapeutics for endo-\nmetriosis. Expert Opinion on Pharmacothera-\npy. 2023;24(8):903-916.","source_license":"CC0","license_restricted":false}